Minghui L. Duan

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Journal: Hematological oncology

Published: April 27, 2026

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Journal: Hematological oncology

Published: January 14, 2026

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Journal: Blood advances

Published: August 01, 2025

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.

Journal: Current hematologic malignancy reports

Published: June 10, 2025

TET2 mutations in myeloproliferative neoplasms: potential mediation of atrial fibrillation by interleukin-1β and impact on stroke risk in clinical cohorts.

TET2 mutations in myeloproliferative neoplasms: potential mediation of atrial fibrillation by interleukin-1β and impact on stroke risk in clinical cohorts.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 19, 2025

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F-Positive Myeloproliferative Neoplasms.

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F-Positive Myeloproliferative Neoplasms.

Journal: Cancer medicine

Published: January 26, 2025

Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.

Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.

Journal: British journal of haematology

Published: August 15, 2024

Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma.

Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma.

Journal: Frontiers in immunology

Published: August 06, 2024

Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology.

Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology.

Journal: British journal of haematology

Published: July 15, 2024

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.

Journal: Acta haematologica

Published: April 29, 2024

Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia.

Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia.

Journal: Haematologica

Published: December 30, 2023

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Journal: American journal of hematology

Published: June 02, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026